Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing ultegra) multicenter study

Circulation

Volumn 103, Issue 21, 2001, Pages 2572-2578

  Steinhubl, Steven R ^a   Talley, J David ^b   Braden, Gregory A ^d   Tcheng, James E ^e   Casterella, Peter J ^f   Moliterno, David J ^g   Navetta, Frank I ^h   Berger, Peter B ⁱ   Popma, Jeffrey J ^j   Dangas, George ^k   Gallo, Richard ^l   Sane, David C ^d   Saucedo, Jorge F ^b   Jia, Gang ^g   Lincoff, A Michael ^g   Theroux, Pierre ^l   Holmes, David R ⁱ   Teirstein, Paul S ^f   Kereiakes, Dean J ^c  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f SCRIPPS CLINIC   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h Mother Francis Hospital   (United States)

ⁱ MAYO CLINIC   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^l MONTREAL HEART INSTITUTE   (Canada)

more..

Author keywords

Angioplasty; Complications; Platelets

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; ARTICLE; CLINICAL TRIAL; DEATH; FEMALE; FUNCTION TEST; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 0035967496     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.21.2572     Document Type: Article

References (21)

1. Preclinical development of c7E3 Fab: Mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
2. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa antagonist, in healthy men
3. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
4. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
5. The rapid platelet function assay: An automated and quantitative cartridge-based method
6. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
7. Attainment and maintenance of platelet inhibition by standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
8. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
9. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy
10. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
11. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
12. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
13. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
14. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
15. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors
16. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model
17. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
18. 3 blockade with percutaneous coronary intervention
19. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
20. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
21. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial